If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 171 - 180 of 281
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Objective
Subcutaneous Sonelokimab v Placebo in Moderate to Severe Hidradenitis Suppurativa
Protocol No
DERM-MOONLAKE-M1095-HS-302
Categories
The Impact of Exercise and Dietary Fat Intake on Blood Lipid and Clotting
Objective
The Impact of Exercise and Dietary Fat Intake on Blood Lipid and Clotting
Protocol No
ENDO-IIT-ZHENG-IEDFIBLC
Evaluating Efficacy When Transitioning From a Current Disease Modifying Therapy DMT to Ublituximab -ENHANCE
Objective
Efficacy Transitioning from a Current DMT to Ublituximab
Protocol No
NEURO-TG-ENHANCE
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer
Objective
Testing the role of DNA released from tumor cells into the blood in guiding the use of immunotherapy after surgical removal of the bladder for bladder cancer treatment.
Protocol No
ALLIANCE-A032103-MODERN
Categories
A Phase 1, Multicenter, Open-Label Study of CB-012, a CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Objective
CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With R/R AML
Protocol No
CARIBOU-AMPLIFY-CB12A-AML
Categories
A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN328 Monotherapy and HPN328 with Atezolizumab or Ifinatamab Deruxtecan (I-DXd) in Patients with Advanced Cancers Asso
Objective
Phase 1/2 open-label, multicenter study to evaluate the safety, PK, and pharmacodynamics of HPN328 in patients with SCLC or with advanced solid tumors associated with expression of DLL3. This study will be divided into 2 parts: Dose Escalation (Part 1) and Expansion (Part 2).
Protocol No
HARPOON-HPN328-4001
Categories
A Phase 2 , Open-Label, Multicenter, Randomized Study Evaluating Neoadjuvant Therapy Targeting the Adenosine Immunosuppressive Pathway in Combination with Immune Checkpoint Blockade and Radiation Therapy in Patients with Advanced Pancreatic Ductal Ad
Objective
Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma (AIRPanc)
Protocol No
COLUMBIA-AAAU4206-AIRPANC
Categories
A Phase 1b, Multicenter, Open-Label Study of Valemetostat Tosylate in Combination with Deruxtecan Antibody-Drug Conjugates in Subjects with Solid Tumors
Objective
A Phase 1B Study of Valemetostat in Combination with Deruxtecan in Patients with Solid Tumors
WITH DXd ADCs
WITH DXd ADCs
Protocol No
DAIICHI-DS3201-324
Categories
A Phase 1b/2, Multicenter, Open-Label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody-Drug Conjugate (ADC), in Combination with Atezolizumab with or without Carboplatin as First-Line Induction or Maintenance, in Subjects with Extensive-Stage
Objective
A Phase 1b 2 Study of I-DXd, ADC, in Combination in Patients with ES-SCLC
Protocol No
DAIICHI-SANKYO-DS7300-189
Categories
ADI-PEG 20 or Placebo Plus Gemcitabine and Docetaxel in Previously Treated Subjects with Leiomyosarcoma (ARGSARC): A Randomized, Double Blind, Multi-Center Phase 3 Trial
Objective
A Randomized Phase 3 Trial of ADI-PEG20 in Patients with Leiomeyosarcoma
Protocol No
POLARIS-2022-001-ARGSARC